# Seminar 18: Liver Disease
## Internal Medicine Clerkship
---
## Learning Objectives
By the end of this seminar, students will be able to:
1. Interpret liver function tests and distinguish hepatocellular from cholestatic patterns of liver injury using aminotransferase and alkaline phosphatase ratios
2. Recognize the clinical presentation and diagnostic criteria of acute liver failure and apply appropriate initial management including N-acetylcysteine for acetaminophen toxicity
3. Identify the major etiologies of cirrhosis and assess disease severity using the Child-Pugh classification and MELD score
4. Diagnose and manage the principal complications of cirrhosis including ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome
5. Apply appropriate serologic testing and treatment strategies for viral hepatitis B and C
6. Describe the indications, contraindications, and prioritization system for liver transplantation
---
## Seminar Outline
### Section 1: Liver Test Interpretation
The interpretation of liver biochemical tests begins with recognizing two fundamental patterns of liver injury that reflect distinct pathophysiologic mechanisms and point toward different diagnostic categories. The hepatocellular pattern is characterized by disproportionate elevation of the aminotransferases, aspartate aminotransferase and alanine aminotransferase, relative to alkaline phosphatase, reflecting direct injury to hepatocytes with release of intracellular enzymes into the bloodstream. Aminotransferase elevations exceeding 300 IU/L generally suggest acute hepatocellular injury from causes such as viral hepatitis, drug-induced liver injury, or ischemic hepatopathy. A distinctive pattern recognized in alcoholic liver disease is the AST-to-ALT ratio exceeding 2:1, which results from the mitochondrial injury caused by alcohol and the relative depletion of pyridoxal phosphate, a cofactor required for ALT synthesis. This ratio, while not pathognomonic, should raise clinical suspicion for alcohol-related liver injury when present in the appropriate clinical context.
The cholestatic pattern is defined by disproportionate elevation of alkaline phosphatase, typically exceeding three times the upper limit of normal, relative to the aminotransferases, reflecting impaired bile formation or flow. Gamma-glutamyl transferase elevation serves as a confirmatory test for the hepatic origin of elevated ALP, as alkaline phosphatase may also originate from bone, placenta, or intestinal sources. Bilirubin is characteristically elevated in the cholestatic pattern, reflecting impaired hepatic conjugation and biliary excretion. The differential diagnosis of cholestatic liver injury includes extrahepatic biliary obstruction from gallstones or malignancy, primary biliary cholangitis, primary sclerosing cholangitis, and drug-induced cholestasis. Imaging with ultrasound or magnetic resonance cholangiopancreatography is essential to distinguish intrahepatic from extrahepatic cholestasis, as the presence of biliary dilation indicates mechanical obstruction requiring procedural intervention.
True liver function is assessed by a separate set of tests that measure the synthetic and metabolic capacity of the liver parenchyma rather than simply reflecting hepatocyte injury. Serum albumin, synthesized exclusively by the liver with a half-life of approximately 21 days, decreases in chronic liver disease as the functional hepatocyte mass diminishes, making it a marker of chronic rather than acute hepatic dysfunction. The prothrombin time and international normalized ratio reflect the synthesis of vitamin K-dependent clotting factors II, VII, IX, and X, and because factor VII has the shortest half-life of approximately 6 hours, the PT/INR is one of the earliest indicators of acute hepatic synthetic failure. Bilirubin reflects the liver's capacity for conjugation and excretion and is elevated in both hepatocellular and cholestatic injury. Thrombocytopenia in the setting of liver disease serves as an indirect marker of portal hypertension, resulting from splenic sequestration due to congestive splenomegaly and decreased hepatic production of thrombopoietin.
Pattern recognition across the full panel of liver biochemical tests enables the experienced clinician to rapidly narrow the differential diagnosis and direct the evaluation efficiently. Acute viral or toxic hepatitis produces very high aminotransferases, often exceeding 1000 IU/L, with normal or mildly elevated alkaline phosphatase and variable bilirubin elevation. Cholestatic conditions show the inverse pattern with high ALP, high bilirubin, and mild aminotransferase elevation. Cirrhosis from any cause typically produces only mild elevations of all markers because the loss of hepatocyte mass limits the degree of enzyme release, while synthetic markers including albumin and INR are characteristically abnormal. Infiltrative processes such as hepatic metastases, lymphoma, and amyloidosis produce elevated ALP with relatively preserved aminotransferases and bilirubin. Understanding these patterns prevents unnecessary and costly testing by directing the clinician toward the most likely diagnostic category from the outset.
Panel A: Side-by-side comparison of hepatocellular versus cholestatic patterns of liver injury showing characteristic AST/ALT, ALP, GGT, and bilirubin profiles with representative etiologies. Panel B: Diagram of synthetic liver function tests showing albumin with its 21-day half-life, PT/INR reflecting clotting factor production, and bilirubin reflecting conjugation and excretion capacity. Panel C: Decision algorithm for evaluating elevated ALP starting with GGT confirmation of hepatic origin and progressing through imaging to distinguish intrahepatic from extrahepatic cholestasis. Panel D: Pattern recognition matrix showing four classic liver injury profiles including acute hepatitis, cholestasis, cirrhosis, and infiltrative disease with their expected liver test results.
### Section 2: Acute Liver Disease
Acute liver failure is a rare but devastating clinical syndrome defined by the triad of hepatic encephalopathy, coagulopathy with an INR of 1.5 or greater, and illness duration of less than 26 weeks in a patient without preexisting liver disease. The absence of prior liver disease is a critical criterion that distinguishes acute liver failure from acute-on-chronic liver failure, a separate entity with different prognostic implications and management considerations. Acute liver failure is further subclassified by the interval between jaundice onset and encephalopathy development: hyperacute within 7 days, acute from 8 to 28 days, and subacute from 29 days to 26 weeks. Paradoxically, hyperacute liver failure, most commonly caused by acetaminophen overdose, carries the best prognosis with the highest rate of spontaneous recovery, while subacute liver failure has the worst prognosis and the highest likelihood of requiring transplantation.
The etiologies of acute liver failure vary geographically, with acetaminophen toxicity being the most common cause in the United States and Western Europe, accounting for approximately 40 to 50% of cases. Drug-induced liver injury from medications other than acetaminophen constitutes the second most common category. Viral hepatitis, particularly hepatitis A and B, remains an important cause worldwide, with herpes simplex virus being a less common but rapidly progressive and often fatal etiology if not treated promptly with acyclovir. Ischemic hepatopathy, colloquially termed shock liver, results from acute hemodynamic compromise and produces a characteristic pattern of rapidly rising and rapidly falling aminotransferases. Autoimmune hepatitis may present as acute liver failure, particularly in young women, and responds to corticosteroid therapy. Wilson disease should be considered in any patient under 40 with acute liver failure, as it requires specific diagnostic testing and emergent liver transplantation because medical therapy is ineffective in the acute fulminant presentation.
Acetaminophen toxicity merits detailed discussion because of its frequency, predictable clinical course, and availability of an effective antidote. Toxicity occurs when the dose exceeds the liver's capacity to conjugate acetaminophen through glucuronidation and sulfation, shunting metabolism to the cytochrome P450 system, which generates the hepatotoxic metabolite NAPQI. Glutathione normally detoxifies NAPQI, but when glutathione stores are depleted by excessive NAPQI production, the reactive metabolite binds to hepatocellular proteins and causes centrilobular necrosis. The toxic threshold is generally considered to be 150 mg/kg or 7.5 grams in a single ingestion, though chronic alcohol use and fasting can lower this threshold by inducing CYP2E1 and depleting glutathione stores, respectively. The Rumack-Matthew nomogram guides treatment decisions for acute single-time-point ingestions by plotting serum acetaminophen levels against time since ingestion. N-acetylcysteine, which replenishes glutathione stores, is the specific antidote and is most effective when administered within 8 hours of ingestion, though benefit has been demonstrated even in patients presenting up to 24 hours after ingestion and in patients with established liver failure.
The management of acute liver failure requires intensive care unit admission and a systematic approach to organ support while simultaneously evaluating for transplant candidacy. Close monitoring of blood glucose is essential because hepatic glycogen stores are rapidly depleted, and hypoglycemia may worsen cerebral edema. Coagulopathy should not be corrected with fresh frozen plasma unless there is active bleeding or an invasive procedure is planned, as the INR serves as a critical prognostic marker and its correction obscures the trajectory of liver function. Hepatic encephalopathy management includes avoidance of sedating medications, which can worsen mental status, and monitoring for cerebral edema, the leading cause of death in acute liver failure. Intracranial pressure monitoring may be indicated in patients with grade III or IV encephalopathy. Early referral to a liver transplant center is imperative because the window of opportunity for transplantation may close rapidly as multiorgan failure develops, and the King's College criteria provide prognostic scoring for acetaminophen and non-acetaminophen etiologies to identify patients unlikely to survive without transplantation.
Panel A: Diagnostic criteria for acute liver failure showing the triad of encephalopathy, INR greater than or equal to 1.5, and duration less than 26 weeks with the subclassification into hyperacute, acute, and subacute categories. Panel B: Pie chart of acute liver failure etiologies in the United States showing acetaminophen as the most common cause followed by drug-induced, viral, ischemic, autoimmune, and Wilson disease. Panel C: Acetaminophen toxicity pathophysiology diagram showing normal conjugation pathways, CYP450 generation of NAPQI, glutathione depletion, and the mechanism of N-acetylcysteine rescue. Panel D: Acute liver failure management algorithm showing ICU admission, glucose monitoring, coagulopathy management, encephalopathy assessment, and transplant evaluation with King's College criteria.
### Section 3: Chronic Liver Disease and Cirrhosis
Cirrhosis represents the final common pathway of chronic liver disease, characterized histologically by diffuse hepatic fibrosis with formation of regenerative nodules that distort the normal hepatic architecture and disrupt portal blood flow. The causes of cirrhosis in the United States are dominated by three etiologies: alcohol-related liver disease accounts for 30 to 40% of cases, chronic hepatitis C for 20 to 30%, and nonalcoholic fatty liver disease and nonalcoholic steatohepatitis for an increasing proportion that now rivals hepatitis C. Chronic hepatitis B is a major cause worldwide, particularly in endemic regions of Asia and Africa. Less common etiologies include autoimmune hepatitis, which occurs predominantly in women and responds to immunosuppressive therapy; primary biliary cholangitis and primary sclerosing cholangitis, which represent cholestatic causes; and metabolic conditions including hereditary hemochromatosis, Wilson disease, and alpha-1 antitrypsin deficiency. Identifying the specific etiology of cirrhosis is essential because many causes have specific treatments that can halt or slow disease progression.
The clinical features of cirrhosis reflect both the loss of hepatic synthetic and metabolic function and the hemodynamic consequences of portal hypertension. Jaundice develops as conjugation and excretion of bilirubin become impaired. Ascites, the accumulation of fluid within the peritoneal cavity, is the most common complication of cirrhosis and results from the combined effects of portal hypertension, splanchnic vasodilation, and renal sodium retention. Spider angiomata, palmar erythema, and gynecomastia reflect the hyperestrogenic state that develops when the cirrhotic liver fails to metabolize estrogen adequately. Caput medusae, the visible distension of periumbilical veins, occurs when portal hypertension causes the reopening of the paraumbilical veins that shunt blood from the portal to the systemic venous circulation. Splenomegaly results from passive congestion due to elevated portal venous pressure and contributes to the thrombocytopenia, leukopenia, and anemia of hypersplenism.
Laboratory abnormalities in cirrhosis reflect the progressive loss of hepatic function and the secondary consequences of portal hypertension. Hypoalbuminemia results from decreased hepatic synthesis and is both a marker of disease severity and a contributor to the pathophysiology of ascites through reduced intravascular oncotic pressure. Prolongation of the PT/INR reflects decreased synthesis of coagulation factors and indicates advanced disease. Thrombocytopenia results primarily from splenic sequestration in the setting of congestive splenomegaly but is compounded by decreased hepatic production of thrombopoietin, the primary regulator of platelet production. Elevated bilirubin reflects impaired hepatic excretion and conjugation. Hyponatremia, when present, is dilutional and results from non-osmotic stimulation of antidiuretic hormone secretion in the setting of effective arterial underfilling, and its development indicates advanced disease with a poor prognosis.
The Child-Pugh classification system provides a clinically practical method for assessing the severity of cirrhosis using five variables, each scored from 1 to 3 points. The variables include total bilirubin, serum albumin, INR, degree of ascites, and grade of hepatic encephalopathy. Scores of 5 to 6 define Class A (compensated), 7 to 9 define Class B (significant functional compromise), and 10 to 15 define Class C (decompensated) cirrhosis. The Child-Pugh score has been used for decades to estimate operative risk and overall prognosis, with one-year survival rates of approximately 100% for Class A, 80% for Class B, and 45% for Class C. While the Child-Pugh score remains useful for clinical communication and surgical risk assessment, the MELD score has largely supplanted it for transplant allocation because of its superior statistical properties and continuous rather than categorical nature.
Panel A: Bar chart showing the relative frequency of cirrhosis etiologies in the United States including alcohol, hepatitis C, NAFLD/NASH, hepatitis B, autoimmune hepatitis, and metabolic conditions. Panel B: Anatomical diagram of a cirrhotic patient showing clinical findings including jaundice, spider angiomata, gynecomastia, caput medusae, ascites, palmar erythema, and splenomegaly with their pathophysiologic explanations. Panel C: Laboratory profile of cirrhosis showing decreased albumin, elevated INR, thrombocytopenia, elevated bilirubin, and dilutional hyponatremia with their pathophysiologic mechanisms. Panel D: Child-Pugh scoring table showing the five variables with their point assignments and the three classes with corresponding one-year survival rates and clinical implications.
### Section 4: Complications of Cirrhosis - Ascites
The pathophysiology of ascites in cirrhosis involves a complex interplay of hemodynamic and neurohormonal derangements that ultimately result in renal sodium and water retention. Portal hypertension, the initiating event, increases hydrostatic pressure within the hepatic sinusoids and promotes transudation of fluid into the peritoneal cavity. Simultaneously, splanchnic arteriolar vasodilation, mediated primarily by nitric oxide, reduces effective arterial blood volume and triggers compensatory activation of the renin-angiotensin-aldosterone system, the sympathetic nervous system, and non-osmotic release of antidiuretic hormone. These neurohormonal responses promote avid renal sodium and water retention, perpetuating and worsening the ascites. The contribution of hypoalbuminemia further reduces plasma oncotic pressure, favoring fluid extravasation from the intravascular compartment into the peritoneal cavity.
Diagnostic paracentesis is the single most important initial diagnostic procedure in any patient presenting with new-onset ascites or in any patient with known ascites who develops clinical deterioration. The serum-ascites albumin gradient, calculated by subtracting the ascitic fluid albumin concentration from the serum albumin concentration, is the key discriminating test. A SAAG of 1.1 g/dL or greater indicates that ascites is due to portal hypertension, as seen in cirrhosis, heart failure, and Budd-Chiari syndrome, with an accuracy exceeding 97%. A SAAG below 1.1 g/dL indicates a non-portal hypertensive etiology such as peritoneal carcinomatosis, tuberculosis, nephrotic syndrome, or pancreatic ascites. Cell count with differential is obtained simultaneously to evaluate for spontaneous bacterial peritonitis, with a polymorphonuclear leukocyte count of 250 per cubic millimeter or greater being diagnostic even in the absence of positive cultures. Additional studies including total protein, glucose, LDH, and cytology are sent based on clinical suspicion for specific etiologies.
The treatment of cirrhotic ascites follows a stepwise approach beginning with sodium restriction and escalating to diuretic therapy and therapeutic paracentesis. Dietary sodium restriction to less than 2 grams per day is the foundation of ascites management and may be sufficient as a sole intervention in mild cases. Pharmacologic therapy combines spironolactone, an aldosterone antagonist that addresses the central neurohormonal disturbance, with furosemide, a loop diuretic that enhances sodium excretion. The classic starting regimen is spironolactone 100 mg daily combined with furosemide 40 mg daily, maintaining the 100:40 ratio as doses are titrated upward to a maximum of spironolactone 400 mg and furosemide 160 mg daily. This ratio is designed to maintain potassium balance by counteracting the potassium-wasting effect of furosemide with the potassium-sparing effect of spironolactone. Therapeutic large-volume paracentesis is performed for tense ascites causing respiratory compromise or abdominal discomfort, with albumin infusion of 6 to 8 grams per liter of fluid removed when more than 5 liters is drained to prevent post-paracentesis circulatory dysfunction.
Refractory ascites, defined as ascites that cannot be controlled despite maximum-dose diuretics and sodium restriction or that recurs rapidly after therapeutic paracentesis, occurs in approximately 5 to 10% of patients with cirrhotic ascites and signals a poor prognosis. Serial large-volume paracentesis every 2 to 3 weeks provides symptomatic relief but does not address the underlying pathophysiology. Transjugular intrahepatic portosystemic shunt placement creates an artificial communication between the portal and hepatic venous systems, effectively reducing portal pressure and improving sodium excretion, and has been shown to improve transplant-free survival in selected patients with refractory ascites. However, TIPS carries a significant risk of hepatic encephalopathy due to the shunting of portal blood past the liver, and is contraindicated in patients with pre-existing severe encephalopathy, advanced liver failure with MELD score above 18 to 20, or congestive heart failure. Liver transplantation is the definitive treatment for refractory ascites and should be considered in all eligible patients.
Panel A: Pathophysiology diagram of ascites formation showing portal hypertension, splanchnic vasodilation, RAAS activation, ADH release, and renal sodium retention with the role of hypoalbuminemia. Panel B: Diagnostic paracentesis interpretation showing SAAG calculation with portal hypertensive causes above 1.1 g/dL and non-portal hypertensive causes below 1.1 g/dL with representative etiologies. Panel C: Stepwise treatment algorithm for ascites from sodium restriction through dual diuretic therapy to therapeutic paracentesis with albumin replacement guidelines. Panel D: Refractory ascites management options showing serial paracentesis, TIPS with contraindications and complications, and liver transplantation as definitive therapy.
### Section 5: Complications - SBP and Hepatorenal Syndrome
Spontaneous bacterial peritonitis is a common and potentially lethal infection of ascitic fluid that occurs without an identifiable intra-abdominal surgical source and is diagnosed by an ascitic fluid polymorphonuclear leukocyte count of 250 per cubic millimeter or greater. The infection results from bacterial translocation across a compromised intestinal mucosal barrier, with organisms migrating from the gut lumen into the mesenteric lymph nodes and subsequently into the ascitic fluid. The most common causative organisms are gram-negative enteric bacteria, particularly Escherichia coli and Klebsiella pneumoniae, followed by gram-positive organisms including streptococcal species. Clinical presentation may include fever, abdominal pain, and worsening encephalopathy, but SBP is frequently asymptomatic or presents with subtle findings, necessitating a high index of suspicion and low threshold for diagnostic paracentesis in any cirrhotic patient with clinical deterioration. Culture-negative neutrocytic ascites, in which the PMN count is elevated but cultures are sterile, is treated identically to culture-positive SBP because the clinical significance and prognosis are equivalent.
The treatment of SBP consists of empiric intravenous antibiotics and intravenous albumin, both initiated immediately upon diagnosis without waiting for culture results. Ceftriaxone 2 grams intravenously once daily for 5 days is the standard empiric antibiotic regimen, providing broad-spectrum coverage against the most common gram-negative and gram-positive causative organisms. Intravenous albumin is administered at a dose of 1.5 grams per kilogram on day 1 and 1 gram per kilogram on day 3, based on landmark trial data demonstrating a significant reduction in the incidence of hepatorenal syndrome and mortality when albumin is added to antibiotic therapy. Repeat paracentesis at 48 hours is recommended to confirm a decline in the PMN count by at least 25%, indicating adequate treatment response. Following recovery from an episode of SBP, long-term antibiotic prophylaxis with norfloxacin 400 mg daily or trimethoprim-sulfamethoxazole is indicated to prevent recurrence, as the recurrence rate without prophylaxis exceeds 70% within one year.
Hepatorenal syndrome is a form of functional renal failure that occurs in the setting of advanced cirrhosis and is driven by extreme renal vasoconstriction in response to progressive splanchnic vasodilation and effective arterial underfilling. The kidneys themselves are structurally normal, and the condition is potentially reversible with liver transplantation or improvement in hepatic function. Type 1 hepatorenal syndrome is characterized by rapid deterioration of renal function, defined as a doubling of the serum creatinine to above 2.5 mg/dL within less than 2 weeks, and carries an extremely poor prognosis with median survival of approximately 2 weeks without treatment. Type 2 hepatorenal syndrome follows a more gradual course and is typically associated with refractory ascites. The diagnosis is one of exclusion, requiring the absence of shock, nephrotoxic drug exposure, parenchymal kidney disease, and failure to improve after withdrawal of diuretics and volume expansion with albumin at 1 gram per kilogram for 2 consecutive days.
Treatment of hepatorenal syndrome aims to reverse the hemodynamic derangements driving renal hypoperfusion while bridging the patient to liver transplantation. Volume expansion with intravenous albumin at 20 to 40 grams daily serves as the foundation of therapy by improving effective arterial blood volume. Vasoconstrictors, which counteract splanchnic vasodilation and improve renal perfusion pressure, are the primary pharmacologic intervention. The combination of midodrine, an alpha-1 agonist, and octreotide, a somatostatin analog that reduces splanchnic blood flow, is the most commonly used regimen in the United States. Alternatively, intravenous norepinephrine or terlipressin, a vasopressin analog available in some countries, may be used in the intensive care setting. TIPS may improve renal function in type 2 HRS by reducing portal pressure and improving effective circulating volume. Liver transplantation is the only definitive treatment, and all patients with hepatorenal syndrome should be evaluated for transplant candidacy, as renal function typically recovers following successful transplantation.
Panel A: SBP pathophysiology showing bacterial translocation across the intestinal mucosa into mesenteric lymph nodes and ascitic fluid with common organisms and the diagnostic PMN threshold of 250 per cubic millimeter. Panel B: SBP treatment protocol showing ceftriaxone dosing, albumin infusion schedule on days 1 and 3, repeat paracentesis at 48 hours, and long-term prophylaxis with norfloxacin or TMP-SMX. Panel C: Hepatorenal syndrome pathophysiology diagram showing the cascade from splanchnic vasodilation through effective arterial underfilling to extreme renal vasoconstriction with type 1 versus type 2 classification. Panel D: HRS treatment algorithm showing albumin volume expansion, vasoconstrictor therapy with midodrine plus octreotide or norepinephrine, TIPS consideration for type 2, and liver transplantation as definitive treatment.
### Section 6: Complications - Encephalopathy and Varices
Hepatic encephalopathy is a spectrum of neuropsychiatric abnormalities caused by the accumulation of neurotoxic substances, primarily ammonia, that are normally cleared by the liver through the urea cycle. In cirrhosis, the combination of decreased hepatocyte function and portosystemic shunting allows ammonia and other gut-derived toxins to bypass hepatic metabolism and reach the systemic circulation, where they cross the blood-brain barrier and cause astrocyte swelling, altered neurotransmission, and cerebral edema. The clinical manifestations are graded on a scale from 1 to 4: grade 1 involves subtle personality changes, sleep-wake cycle disturbance, and difficulty with concentration; grade 2 manifests as lethargy, inappropriate behavior, and asterixis, the characteristic flapping tremor of the outstretched hands; grade 3 involves somnolence, marked confusion, and disorientation; and grade 4 represents hepatic coma with loss of consciousness and response only to painful stimuli. Precipitating factors are identified in the majority of episodes and include infection, gastrointestinal bleeding, electrolyte disturbances, constipation, medication effects particularly from sedatives and opioids, and dietary protein excess.
The management of hepatic encephalopathy centers on identification and treatment of the precipitating factor alongside pharmacologic reduction of ammonia production and absorption. Lactulose, a non-absorbable disaccharide, is the first-line treatment and works through two complementary mechanisms: it is metabolized by colonic bacteria to organic acids that lower the colonic pH, trapping ammonia as the non-absorbable ammonium ion, and its osmotic laxative effect accelerates fecal elimination of ammonia-producing bacteria and their substrates. The standard dose is 30 to 45 mL administered three to four times daily, titrated to achieve two to three soft bowel movements per day. Rifaximin, a non-absorbable antibiotic, is added as adjunctive therapy in patients who fail to respond adequately to lactulose alone or who experience recurrent episodes of encephalopathy, and it has been shown to significantly reduce the risk of recurrent encephalopathy when used in combination with lactulose. Importantly, dietary protein restriction is no longer recommended as a management strategy because it worsens the already precarious nutritional status of cirrhotic patients without providing meaningful reduction in encephalopathy risk.
Esophageal varices are dilated submucosal veins in the esophagus that develop as a consequence of portal hypertension, as blood is diverted from the high-pressure portal venous system through collateral pathways to the low-pressure systemic venous circulation. Approximately 50% of patients with cirrhosis have esophageal varices at the time of diagnosis, and the risk of variceal hemorrhage is approximately 30% per year in patients with large varices, making this one of the most feared complications of portal hypertension. Screening with esophagogastroduodenoscopy is recommended at the time of cirrhosis diagnosis and at regular intervals thereafter based on the presence and size of varices and the degree of hepatic decompensation. High-risk features for bleeding include large variceal size, the presence of red wale marks on the variceal surface indicating areas of thin-walled ectasia, and advanced Child-Pugh class.
The prevention and treatment of variceal bleeding follow a protocol stratified by whether the patient has never bled (primary prophylaxis), is actively bleeding (acute management), or has survived a prior bleeding episode (secondary prophylaxis). Primary prophylaxis employs either nonselective beta-blockers such as propranolol or nadolol, which reduce portal pressure by decreasing cardiac output and splanchnic blood flow, or endoscopic variceal band ligation, which mechanically obliterates varices. Both approaches reduce the risk of first variceal hemorrhage by approximately 50%. Acute variceal bleeding is a medical emergency managed with a combination of vasoactive drugs, typically octreotide, to reduce portal pressure, prophylactic antibiotics such as ceftriaxone to prevent bacterial infection that worsens portal hypertension and rebleeding risk, and urgent endoscopic band ligation to achieve hemostasis. Secondary prophylaxis combines nonselective beta-blockers with endoscopic band ligation, as the combination is superior to either intervention alone. TIPS is reserved for patients with refractory or recurrent variceal bleeding despite optimal medical and endoscopic therapy and can achieve portal decompression but carries risks of encephalopathy and liver failure.
Panel A: Hepatic encephalopathy grading scale showing grades 1 through 4 with clinical features, common precipitants, and the pathophysiology of ammonia crossing the blood-brain barrier. Panel B: Lactulose mechanism of action showing colonic acidification trapping ammonia as ammonium with osmotic laxative effect and rifaximin as adjunctive therapy reducing ammonia-producing bacteria. Panel C: Endoscopic images of esophageal varices showing small and large varices with red wale marks and post-banding appearance with screening and surveillance schedule. Panel D: Variceal bleeding management flowchart showing primary prophylaxis with beta-blockers or band ligation, acute management with octreotide plus antibiotics plus band ligation, and secondary prophylaxis with combination therapy and TIPS as rescue.
### Section 7: Viral Hepatitis
Hepatitis A is an RNA virus transmitted through the fecal-oral route, typically via contaminated food or water, and causes an exclusively acute hepatitis that does not progress to chronic infection. The clinical presentation ranges from asymptomatic infection in young children to a symptomatic illness characterized by jaundice, malaise, nausea, and abdominal pain in adults, with the severity of symptoms generally increasing with age at the time of infection. Diagnosis is established by detection of anti-HAV IgM antibody, which appears at the onset of symptoms and remains detectable for approximately 3 to 6 months. Treatment is entirely supportive, as the infection is self-limited in the vast majority of cases, though rare cases of fulminant hepatic failure can occur, particularly in patients with underlying chronic liver disease. Prevention through vaccination is highly effective, and universal childhood vaccination has dramatically reduced the incidence of hepatitis A in countries with established vaccination programs.
Hepatitis B is a DNA virus transmitted through blood, sexual contact, and perinatal exposure, and its clinical significance lies in its capacity to cause chronic infection leading to cirrhosis and hepatocellular carcinoma. The serologic interpretation of hepatitis B requires understanding of multiple markers: hepatitis B surface antigen indicates active infection, anti-HBs antibody indicates immunity either from vaccination or resolved infection, anti-HBc IgM indicates acute infection, and anti-HBc IgG indicates prior exposure. Hepatitis B e antigen is a marker of high viral replication and infectivity, while HBV DNA quantification provides the most accurate assessment of viral load. The natural history of hepatitis B varies dramatically depending on the age at acquisition, with perinatal transmission resulting in chronic infection in over 90% of cases compared to less than 5% in adults infected as immunocompetent adults. The diagnosis of chronic hepatitis B requires the persistence of HBsAg for more than 6 months.
Treatment of chronic hepatitis B aims to suppress viral replication, prevent progression to cirrhosis and hepatocellular carcinoma, and reduce transmission risk. The decision to initiate treatment is based on the assessment of viral replication (HBV DNA level), degree of liver inflammation (ALT level), and stage of fibrosis. First-line antiviral agents include tenofovir disoproxil fumarate and entecavir, both of which are potent nucleoside or nucleotide analogs with high barriers to resistance. Treatment is typically long-term and often indefinite, as viral eradication is rarely achieved and premature discontinuation risks virologic relapse and hepatitis flares. The goal of therapy is sustained suppression of HBV DNA to undetectable levels, normalization of ALT, and ideally, seroconversion from HBeAg-positive to anti-HBe-positive status. All patients with chronic hepatitis B require regular surveillance for hepatocellular carcinoma with ultrasound and alpha-fetoprotein every 6 months, regardless of the stage of fibrosis.
Hepatitis C is an RNA virus transmitted primarily through blood exposure, with intravenous drug use being the most common route of acquisition in the United States. Acute infection is typically asymptomatic, and approximately 80% of acutely infected individuals progress to chronic infection, which can silently cause progressive hepatic fibrosis over decades. Diagnosis involves a two-step process: initial screening with anti-HCV antibody, which indicates exposure but not necessarily active infection, followed by confirmatory testing with HCV RNA to detect active viremia. The treatment landscape for hepatitis C has been revolutionized by direct-acting antivirals, which target specific proteins essential for viral replication, including NS3/4A protease inhibitors, NS5A inhibitors, and NS5B polymerase inhibitors. Combination DAA regimens achieve sustained virologic response rates exceeding 95% across all genotypes with treatment durations of 8 to 12 weeks and minimal side effects. Cure of hepatitis C, defined as sustained virologic response at 12 weeks post-treatment, halts liver disease progression, reduces the risk of hepatocellular carcinoma, and eliminates transmission risk.
Panel A: Hepatitis A clinical course showing fecal-oral transmission, acute symptomatic illness, anti-HAV IgM and IgG appearance over time, and the self-limited nature of infection. Panel B: Hepatitis B serologic marker interpretation chart showing HBsAg, anti-HBs, anti-HBc IgM, anti-HBc IgG, HBeAg, and HBV DNA in acute infection, chronic infection, resolved infection, and vaccination. Panel C: Hepatitis B treatment algorithm showing assessment of HBV DNA, ALT, and fibrosis stage with first-line agents tenofovir and entecavir and treatment goals. Panel D: Hepatitis C diagnostic and treatment pathway from anti-HCV antibody screening through HCV RNA confirmation to DAA therapy with greater than 95% cure rates and outcome benefits including halted fibrosis progression and reduced HCC risk.
### Section 8: Alcoholic and Fatty Liver Disease
Alcoholic liver disease encompasses a spectrum of hepatic pathology that progresses through distinct stages determined by the pattern and duration of alcohol consumption. Alcoholic steatosis, or fatty liver, is the earliest and most common manifestation, present in virtually all heavy drinkers, and is fully reversible with abstinence. Alcoholic steatohepatitis represents the progression to active hepatocellular inflammation and necrosis, characterized by the distinctive AST-to-ALT ratio exceeding 2:1, with aminotransferase levels typically remaining below 500 IU/L. Cirrhosis represents the end stage of progressive fibrosis and is irreversible, though abstinence can still dramatically improve survival and hepatic function even in patients with established cirrhosis. Acute alcoholic hepatitis is a distinct clinical syndrome that can occur at any point along the spectrum and carries a high short-term mortality, representing one of the most feared complications of alcohol use disorder.
Acute alcoholic hepatitis presents as a clinical syndrome of jaundice, fever, and tender hepatomegaly in the setting of recent heavy alcohol use. The laboratory profile characteristically shows an AST-to-ALT ratio exceeding 2:1 with aminotransferases typically remaining below 500 IU/L, markedly elevated bilirubin, and leukocytosis with a left shift. The Maddrey discriminant function, calculated as 4.6 times the prolongation of the prothrombin time plus the total bilirubin, is the primary prognostic scoring tool. A discriminant function of 32 or greater indicates severe alcoholic hepatitis with a 30-day mortality of 30 to 50% and identifies patients who may benefit from pharmacologic therapy. Prednisolone 40 mg daily for 28 days is the standard treatment for severe alcoholic hepatitis, though its benefit is modest and is primarily seen in patients who demonstrate improvement in bilirubin levels within the first week, assessed by the Lille model. Response at day 7, defined by a Lille score below 0.45, predicts benefit from continuing corticosteroid therapy, while non-responders should have steroids discontinued due to the risk of infection without therapeutic benefit.
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis represent a parallel spectrum of hepatic steatosis and inflammation occurring in the absence of significant alcohol consumption, driven primarily by insulin resistance and the metabolic syndrome. NAFLD is defined by the presence of hepatic steatosis affecting more than 5% of hepatocytes without significant alcohol consumption, and it is now the most common liver disease in Western countries, affecting approximately 25 to 30% of the adult population. NASH represents the subset of NAFLD with active hepatocellular inflammation and ballooning degeneration, which carries a risk of progressive fibrosis leading to cirrhosis. Risk factors for NAFLD and NASH include obesity, type 2 diabetes mellitus, hypertriglyceridemia, and metabolic syndrome. Diagnosis requires imaging demonstrating hepatic steatosis along with exclusion of significant alcohol use and other liver diseases, though liver biopsy remains the gold standard for distinguishing simple steatosis from NASH and for staging fibrosis.
Treatment of NAFLD and NASH centers on lifestyle modification as the cornerstone of management, with pharmacologic therapy reserved for patients with biopsy-proven NASH and significant fibrosis. Weight loss of at least 7 to 10% of body weight has been shown to improve hepatic inflammation and fibrosis and is the single most effective intervention. Regular aerobic exercise independently improves hepatic steatosis even without significant weight loss. Optimization of comorbid metabolic conditions including diabetes, hyperlipidemia, and hypertension is essential. Pharmacologic options include vitamin E at 800 IU daily, which has been shown to improve histology in non-diabetic patients with NASH, and pioglitazone, a thiazolidinedione that improves insulin sensitivity and has demonstrated histologic benefit in both diabetic and non-diabetic patients. The prognosis of NAFLD and NASH is determined by the stage of fibrosis, as liver-related mortality increases dramatically with advancing fibrosis. Patients with NASH-related cirrhosis require the same surveillance and management protocols as cirrhosis from any cause, including screening for hepatocellular carcinoma.
Panel A: Alcoholic liver disease spectrum diagram showing progression from steatosis through steatohepatitis to cirrhosis with reversibility at each stage and the overlay of acute alcoholic hepatitis. Panel B: Acute alcoholic hepatitis diagnostic and treatment algorithm showing Maddrey discriminant function calculation, threshold of 32 for severe disease, prednisolone treatment, and Lille score assessment at day 7. Panel C: NAFLD and NASH epidemiology and risk factor diagram showing the relationship between obesity, insulin resistance, metabolic syndrome, and hepatic steatosis with the progression pathway from simple steatosis to NASH to cirrhosis. Panel D: NAFLD/NASH treatment hierarchy showing lifestyle modification as the foundation with weight loss targets, exercise recommendations, pharmacologic options including vitamin E and pioglitazone, and the role of bariatric surgery.
### Section 9: Other Liver Diseases
Autoimmune hepatitis is a chronic inflammatory liver disease caused by immune-mediated destruction of hepatocytes and is characterized by elevated serum immunoglobulin G levels, circulating autoantibodies, and interface hepatitis on liver biopsy. The disease occurs predominantly in women and has a bimodal age distribution with peaks in adolescence and around age 50. Type 1 autoimmune hepatitis, the most common form, is associated with antinuclear antibodies and anti-smooth muscle antibodies, while type 2 is characterized by anti-liver-kidney microsomal antibodies. The presentation ranges from asymptomatic transaminase elevation to acute hepatitis mimicking acute liver failure, and a high index of suspicion is required because autoimmune hepatitis is a treatable cause of liver disease that, if left untreated, progresses to cirrhosis in the majority of patients. Treatment with prednisone, often combined with azathioprine as a steroid-sparing agent, produces biochemical and histologic remission in approximately 65 to 80% of patients. The response to immunosuppressive therapy is generally excellent, but relapse is common upon discontinuation, and many patients require long-term maintenance therapy.
Primary biliary cholangitis, formerly known as primary biliary cirrhosis, is a chronic cholestatic liver disease caused by immune-mediated destruction of the small intrahepatic bile ducts, leading to cholestasis, progressive fibrosis, and eventually cirrhosis. The disease predominantly affects middle-aged women and commonly presents with fatigue and pruritus, often preceding the development of jaundice by years. The cholestatic biochemical profile with elevated alkaline phosphatase and the presence of antimitochondrial antibodies in approximately 95% of patients are the diagnostic hallmarks. Liver biopsy, while not always required for diagnosis when the clinical and serologic picture is typical, shows characteristic granulomatous destruction of bile ducts known as florid duct lesions. Ursodeoxycholic acid at 13 to 15 mg/kg/day is the first-line treatment and has been shown to improve biochemical parameters, delay histologic progression, and improve transplant-free survival. Obeticholic acid may be added for patients with an inadequate response to ursodeoxycholic acid.
Primary sclerosing cholangitis is a chronic cholestatic liver disease characterized by progressive inflammation and fibrosis of the intrahepatic and extrahepatic bile ducts, leading to multifocal strictures, cholestasis, and eventually biliary cirrhosis. There is a strong association with inflammatory bowel disease, particularly ulcerative colitis, which is present in approximately 70 to 80% of PSC patients, though the course of PSC does not parallel the activity of the underlying bowel disease. Diagnosis is established by magnetic resonance cholangiopancreatography showing the characteristic beading pattern of alternating strictures and dilations of the bile ducts. Unlike autoimmune hepatitis and primary biliary cholangitis, no medical therapy has been convincingly shown to alter the natural history of PSC, and treatment is primarily directed at managing complications including cholestasis, bacterial cholangitis, dominant strictures, and screening for cholangiocarcinoma, which develops in 10 to 15% of PSC patients. Liver transplantation is the only definitive treatment for advanced PSC, though the disease can recur in the transplanted liver.
Hereditary hemochromatosis is the most common genetic disease in populations of Northern European descent, caused by autosomal recessive mutations in the HFE gene, most commonly C282Y, that result in increased intestinal iron absorption and progressive iron overload affecting the liver, heart, pancreas, joints, and endocrine organs. The classic clinical presentation includes the triad of cirrhosis, diabetes mellitus, and bronze skin pigmentation, though modern patients are more often identified through screening laboratory tests before clinical manifestations develop. Screening relies on transferrin saturation exceeding 45% and elevated serum ferritin, with genetic testing for HFE mutations confirming the diagnosis. The liver is the organ most commonly and most severely affected, with iron deposition leading to progressive fibrosis and cirrhosis, and patients with hemochromatosis-related cirrhosis have a significantly elevated risk of hepatocellular carcinoma estimated at 20-fold compared to the general population. Treatment with phlebotomy, removing 500 mL of blood (containing approximately 250 mg of iron) at regular intervals, is highly effective at depleting iron stores and preventing organ damage when initiated before cirrhosis develops, with a target ferritin of 50 to 100 ng/mL guiding the frequency of maintenance phlebotomy.
Panel A: Autoimmune hepatitis diagnostic features showing elevated IgG, ANA and anti-smooth muscle antibodies, interface hepatitis on biopsy, and treatment response to prednisone plus azathioprine. Panel B: Primary biliary cholangitis showing antimitochondrial antibody positivity, cholestatic liver profile, florid duct lesion on biopsy, and treatment with ursodeoxycholic acid with biochemical response criteria. Panel C: Primary sclerosing cholangitis showing beading pattern on MRCP, association with ulcerative colitis, cholangiocarcinoma risk, and the lack of proven medical therapy with liver transplantation as definitive treatment. Panel D: Hereditary hemochromatosis showing HFE gene mutations, transferrin saturation and ferritin screening, organ involvement pattern, and phlebotomy treatment protocol with target ferritin levels.
### Section 10: Liver Transplantation
The indications for liver transplantation encompass a range of acute and chronic liver diseases in which the prognosis without transplantation is poor and no alternative effective medical or surgical therapy exists. Acute liver failure from any cause, when the likelihood of spontaneous recovery is low based on prognostic criteria such as the King's College criteria, represents an urgent indication for transplantation. Chronic liver disease with decompensation, defined by the development of ascites, variceal bleeding, hepatic encephalopathy, or hepatorenal syndrome, indicates that the functional hepatic reserve has been exhausted and transplantation should be considered. Hepatocellular carcinoma within the Milan criteria, defined as a single tumor up to 5 centimeters or up to three tumors each 3 centimeters or smaller without vascular invasion or extrahepatic spread, is a well-established transplant indication because the recurrence rate after transplantation is low and the five-year survival is comparable to transplantation for non-malignant indications. Certain metabolic conditions including familial amyloidotic polyneuropathy, primary hyperoxaluria, and urea cycle defects may warrant transplantation even in the absence of significant hepatic dysfunction.
The Model for End-Stage Liver Disease score is a validated continuous scoring system that uses three objective laboratory variables, serum bilirubin, INR, and serum creatinine, to predict 90-day mortality in patients with chronic liver disease and serves as the primary organ allocation tool for liver transplantation in the United States. The MELD score ranges from 6 to 40, with higher scores indicating greater disease severity and mortality risk, and patients with the highest MELD scores receive priority for organ allocation. The MELD-Na modification incorporates serum sodium into the calculation, recognizing that hyponatremia is an independent predictor of mortality in cirrhosis and improving the accuracy of the model. Exception points may be granted for specific indications, such as hepatocellular carcinoma within the Milan criteria, in which the MELD score may not reflect the urgency of transplantation because the risk is tumor progression beyond transplant criteria rather than imminent liver failure. The MELD-based allocation system has significantly reduced waitlist mortality since its implementation in 2002 by prioritizing the sickest patients for available organs.
Contraindications to liver transplantation are divided into absolute and relative categories that must be evaluated during the transplant candidacy assessment. Absolute contraindications include uncontrolled extrahepatic infection, extrahepatic malignancy that is not amenable to curative treatment, severe and irreversible cardiopulmonary disease that would preclude survival of the surgical procedure, and anatomic abnormalities that render the surgery technically impossible. Active alcohol or substance abuse is generally considered a contraindication, with most programs requiring a period of documented sobriety, typically 6 months, though this paradigm is evolving as evidence accumulates supporting early transplantation for severe alcoholic hepatitis in carefully selected patients. Relative contraindications include advanced age, controlled HIV infection, significant psychiatric illness that may impair adherence to the complex post-transplant medical regimen, and inadequate social support systems. The lack of social support is not a reflection of patient worthiness but rather a practical concern about the ability to manage the demanding post-transplant care requirements.
Post-transplant management requires lifelong immunosuppressive therapy and vigilant monitoring for complications including rejection, infection, and disease recurrence. The standard immunosuppressive regimen includes a calcineurin inhibitor such as tacrolimus, often combined with mycophenolate mofetil and corticosteroids that are gradually tapered. Acute cellular rejection occurs in approximately 15 to 25% of recipients within the first year and is diagnosed by rising liver function tests and confirmed by liver biopsy showing portal inflammation with bile duct damage and endotheliitis. Treatment with high-dose corticosteroids is effective in the majority of rejection episodes. Chronic rejection is less common but more resistant to treatment and may require retransplantation. Recurrence of the original liver disease in the graft is an important consideration: hepatitis C can infect the new liver but is now effectively treated with DAAs, NAFLD may recur in the setting of persistent metabolic risk factors, and autoimmune conditions may recur requiring ongoing immunosuppressive therapy. Overall five-year survival after liver transplantation is 70 to 80%, with continued improvements driven by advances in surgical technique, immunosuppression, and post-transplant care.
Panel A: Liver transplant indications organized by category showing acute liver failure, decompensated cirrhosis, hepatocellular carcinoma within Milan criteria, and metabolic conditions with their specific qualifying criteria. Panel B: MELD score calculation showing the three laboratory variables of bilirubin, INR, and creatinine with MELD-Na modification incorporating sodium and the score range from 6 to 40 with corresponding mortality predictions. Panel C: Absolute and relative contraindications to liver transplantation showing uncontrolled infection, extrahepatic malignancy, severe cardiopulmonary disease, and active substance abuse alongside relative factors of age, HIV status, and social support. Panel D: Post-transplant management timeline showing immunosuppressive regimen, rejection surveillance with liver biopsy, disease recurrence monitoring, and overall five-year survival outcome data.
---
## Summary
- LFT patterns: hepatocellular injury shows high AST/ALT with normal ALP; cholestatic injury shows high ALP with normal or mildly elevated AST/ALT
- Acute liver failure: defined by INR of 1.5 or greater plus encephalopathy; acetaminophen is the most common cause; N-acetylcysteine is the antidote
- Cirrhosis causes: alcohol, hepatitis C, and NAFLD are the most common etiologies in the United States
- Child-Pugh and MELD scores assess severity and prognosis; MELD drives transplant allocation
- Ascites: sodium restriction plus spironolactone and furosemide in a 100:40 ratio; SAAG of 1.1 or greater indicates portal hypertension
- SBP: diagnosed by ascitic fluid PMN count of 250 or greater; treat with ceftriaxone plus albumin; prophylaxis to prevent recurrence
- Hepatic encephalopathy: lactulose is first-line therapy; identify and treat precipitants; rifaximin for recurrent episodes
- Varices: nonselective beta-blockers or band ligation for primary prophylaxis; combination therapy for secondary prophylaxis
- HCV is curable with DAAs achieving greater than 95% SVR; HBV requires long-term antiviral therapy with tenofovir or entecavir
- Liver transplant is indicated for acute liver failure, decompensated cirrhosis, and HCC within Milan criteria; MELD score prioritizes allocation
---
## Key Terms
| Term | Definition |
|------|------------|
| Cirrhosis | End-stage chronic liver disease characterized by diffuse fibrosis and regenerative nodules distorting hepatic architecture |
| SAAG | Serum-ascites albumin gradient; value of 1.1 or greater indicates portal hypertension as the cause of ascites |
| SBP | Spontaneous bacterial peritonitis; infection of ascitic fluid diagnosed by PMN count of 250 or greater per cubic millimeter |
| HRS | Hepatorenal syndrome; functional renal failure in advanced cirrhosis caused by extreme renal vasoconstriction |
| MELD | Model for End-Stage Liver Disease; scoring system using bilirubin, INR, and creatinine to predict 90-day mortality |
| Child-Pugh | Classification system for cirrhosis severity using bilirubin, albumin, INR, ascites, and encephalopathy |
| DAA | Direct-acting antiviral; targeted therapy for hepatitis C achieving cure rates exceeding 95% |
| TIPS | Transjugular intrahepatic portosystemic shunt; percutaneous procedure to reduce portal pressure |
---
*This content is subject to the [MIT License](https://opensource.org/licenses/MIT). © 2024–2026 Hibbert School of Medicine.*